利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.012 秒)

    COMPOSITIONS FOR USE IN THE TREATMENT OF LEUKAEMIA
    3.
    发明公开
    COMPOSITIONS FOR USE IN THE TREATMENT OF LEUKAEMIA 审中-公开

    公开(公告)号：EP4000617A1

    公开(公告)日：2022-05-25

    申请号：EP20383021.1

    申请日：2020-11-23

    申请人： Fundació Institut de Recerca Contra la Leucèmia Josep Carreras

    发明人： MUÑOZ RISUEÑO, Ruth ,  CORNET MASANA, Josep Maria ,  CARBÓ MARQUÉS, José María

    IPC分类号： A61K31/381 ,  A61K31/4535 ,  A61K31/496 ,  A61P35/02

    摘要： The present invention relates to a method of treating a warm-blooded animal, especially a human subject, having leukaemia, preferably acute myeloid leukemia (AML), B and T acute lymphoblastic leukemias (B-ALL and T-ALL), or chronic myeloid leukemia (CML), or a lymphoma or a solid tumour, comprising administering to said animal a therapeutically effective amount of a compound having any of the formulae identified throughout the present specification, optionally together or in combination with a conventional compound or compound mixture useful in any of said treatments, in particular a topoisomerase II inhibitor, an antimetabolite, or an antitumor antibiotic, and optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential use; and to a pharmaceutical composition and a commercial package comprising said compound.

    LOW INPUT CHROMOSOME CONFORMATION CAPTURE METHODS
    9.
    发明公开
    LOW INPUT CHROMOSOME CONFORMATION CAPTURE METHODS 审中-公开

    公开(公告)号：EP4350003A1

    公开(公告)日：2024-04-10

    申请号：EP22382944.1

    申请日：2022-10-06

    申请人： Fundació Institut de Recerca Contra la Leucèmia Josep Carreras ,  Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP)

    发明人： JAVIERRE MARTÍNEZ, Biola María

    IPC分类号： C12Q1/6841

    摘要： The present invention provides a method for identifying at least one nucleic acid sequence that interacts with at least one target nucleic acid sequence, the method comprising the steps of: (a) crosslinking a nucleic acid composition comprising the at least one target nucleic acid sequence; (b) fragmenting the crosslinked nucleic acid composition, thereby producing fragmented crosslinked nucleic acid sequences; (c) marking the ends of the nucleic acid sequences with an affinity tag;(d) ligating the nucleic acid sequences to produce nucleic acid sequences with ligation junctions comprising the affinity tag; (e) reversing the crosslinking; (f) shearing the nucleic acid sequences; (g) purifying the nucleic acid sequences with ligation junctions comprising the affinity tag by contacting with a ligand of the affinity tag; (h) A-tailing and amplifying the purified nucleic acid sequences; (i) isolating the amplified nucleic acid sequences that comprise the at least one target nucleic acid sequence or a portion of the at least one target nucleic acid sequence; and (j) sequencing the isolated nucleic acid sequences to identify nucleic acid sequences that interact with the at least one target nucleic sequence; with the proviso that the method does not comprise a step to remove the affinity tag from non-ligated ends.